Researchers have reported that two widely used medications may help reverse the progression of metabolic dysfunction‑associated steatotic liver disease (MASLD) and its more severe form, metabolic dysfunction‑associated steatohepatitis (MASH). The findings, highlighted in a recent study covered by ScienceDaily, suggest that repurposing these drugs could offer a new therapeutic avenue for patients struggling with liver fat accumulation, particularly those also managing diabetes.
The study examined the effects of the drugs in preclinical models and early clinical observations, noting improvements in liver enzyme levels, reductions in hepatic fat content, and attenuation of fibrosis markers. Experts such as Dr. Scott Isaacs, who spoke with Docwire News, emphasized that targeting MASLD and MASH in patients with diabetes requires a multifaceted approach, where weight management and glycemic control play crucial roles alongside pharmacological interventions.
In parallel, other emerging strategies are gaining attention. Intragastric balloon therapy, discussed in Clinical Advisor, presents a minimally invasive option for weight loss that may indirectly benefit liver health by reducing obesity‑related stress on the liver. Meanwhile, the pharmaceutical race for liver antifibrotics, as reported by EMJ, continues to accelerate, with several compounds in various stages of development aiming to halt or reverse scar tissue formation.
Experts from AJMC point out that weight loss and obesity‑focused drugs are reshaping treatment strategies for MASLD and MASH, offering hope that lifestyle modifications combined with targeted pharmacotherapy could significantly alter disease trajectories. As research progresses, clinicians remain optimistic that these common drugs, either alone or in combination with other interventions, might soon become part of standard care for patients affected by fatty liver disease.
COMMENTS